AOA Health Policy Institute launches blepharitis resource
Click Here to Manage Email Alerts
The American Optometric Association Health Policy Institute has released a new brief to educate the public on blepharitis, its symptoms and treatment options.
“The AOA’s Health Policy Institute is focused on providing expert and research-based analysis to deliver contemporary and meaningful eye health and vision care resources and tools to help inform policy and high-quality comprehensive patient care,” AOA President Steven T. Reed, OD, told Healio.
The resource outlines important information about anterior blepharitis, including that while it does not typically cause permanent vision loss, it can cause significant ocular surface disease and infection and is very common among older adults.
Also highlighted is Demodex blepharitis, a largely underdiagnosed but highly prevalent ocular disease with a high symptom burden and psychosocial effects.
In addition, the brief includes data from recent studies as well as information on treatment options such as selenium, antiparasitics, topical and oral antibiotics, intense pulsed light and microblepharoexfoliation, among others. The recently approved Xdemvy (lotilaner ophthalmic solution 0.25%, Tarsus Pharmaceuticals) for the treatment of Demodex blepharitis, is also discussed.
Read more about
Click Here to Manage Email Alerts